OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS

12 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS

Composition of Certain Financial Statement Captions

Components of selected captions in the consolidated balance sheets are as follows:


	As of December 31,
	2020		2019
	(in millions)
Inventories
Raw materials	$	136.7	$	118.0
Work in process	140.0		121.7
Finished products	525.6		401.2
	$	802.3	$	640.9
Property, plant, and equipment, net
Land	$	97.6	$	98.0
Buildings and leasehold improvements	881.5		619.8
Machinery and equipment	564.9		466.3
Equipment with customers	42.2		35.6
Software	94.2		87.9
Construction in progress	313.3		265.0
	1,993.7		1,572.6
Accumulated depreciation	(598.5)		(512.3)
	$	1,395.2	$	1,060.3

Accrued and other liabilities
Employee compensation and withholdings	$	236.7	$	295.8
Accrued rebates	67.2		67.1
Property, payroll, and other taxes	49.7		51.4
Research and development accruals	52.3		51.4
Litigation settlement (Notes 3 and 18)	37.5		—
Litigation and insurance reserves (Note 18)	23.3		20.0
Taxes payable	18.6		52.9
Fair value of derivatives	39.3		6.4
Accrued marketing expenses	14.3		17.5
Accrued professional services	7.6		10.1
Accrued realignment reserves	14.5		16.7
Accrued relocation related costs	21.0		17.4
Other accrued liabilities	88.2		89.8
	$	670.2	$	696.5

In 2019, the Company recorded a $73.1 million charge to "Cost of Sales," primarily comprised of the write off of inventory related to strategic decisions regarding its transcatheter aortic valve portfolio, including the decision to discontinue its CENTERA program.

Supplemental Cash Flow Information

(in millions)


	Years Ended December 31,
	2020		2019		2018
Cash paid during the year for:
Interest	$	19.9	$	19.9	$	30.1
Income taxes	$	197.9	$	61.5	$	223.7
Amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	29.7	$	28.6	$	—
Non-cash investing and financing transactions:
Fair value of shares issued in payment for contingent consideration liabilities	$	—	$	—	$	34.3

Right-of-use assets obtained in exchange for new lease liabilities	$	39.7	$	49.6	$	—
Capital expenditures accruals	$	80.4	$	50.8	$	18.7

Cash, Cash Equivalents, and Restricted Cash

(in millions)


	Years Ended December 31,
	2020		2019		2018
Cash and cash equivalents	$	1,183.2	$	1,179.1	$	714.1
Restricted cash included in other current assets	16.6		1.6		1.5
Restricted cash included in other assets	0.4		3.7		0.3
Total cash, cash equivalents, and restricted cash	$	1,200.2	$	1,184.4	$	715.9

Amounts included in restricted cash primarily represent funds placed in escrow related to litigation and real estate purchases, and funds restricted for construction.